Inside OpenEvidence’s $12B Rise: The Playbook Winning AI Companies Share
In eleven months, OpenEvidence went from a $1 billion valuation to $12 billion. By April 2026, the company reported that its platform was being used by approximately 65% of US physicians and supported nearly 27 million clinical consultations that month, with much of its adoption attributed to physician word-of-mouth.
Think explosive growth is just about having the best AI tech? It’s not. If you look at the AI companies truly scaling today, their real competitive edge is deep market insight. Too many founders skip this step because they’re rushing to build something impressive instead.
Many view AI as a dragon coming to burn down their industry. But it also represents transformative and generative power. If you cannot outmuscle a force like that, you learn to ride it to become stronger.
As AI shifts from a simple tool to an autonomous agent, completing complex work with less and less human intervention, founders face a clear choice: draw a sword, or learn to fly.
Qian and the Anatomy of a Founder
The I Ching (Book of Changes), an ancient Chinese philosophical text, uses the dragon as a central metaphor in its first hexagram, Qian (The Creative). It tracks a dragon through six stages of maturation — from total obscurity to full command of the sky. It perfectly mirrors the modern founder’s journey.
Peter Diamandis, founder of the XPRIZE Foundation, describes five mindsets that keep people stable and effective through accelerating change: curiosity, abundance, exponential thinking, longevity, and moonshot thinking. Map them onto the dragon’s ascent and you get an operating system for building through the AI era — one altitude at a time, plus a warning at the top that most founders skip.
1. Hidden Dragon — The Curiosity Mindset
“The dragon is hidden. Do not act.”
1. Hidden Dragon — The Curiosity Mindset
At the earliest stage, the market doesn’t know you exist, and that’s fine. This is a research phase. The Curiosity Mindset is the fuel: what specific problem does this technology actually solve, for whom, better than the current alternative? Curiosity prevents premature action and allows you to deeply understand the landscape before making your move.
2. Dragon in the Field — The Abundance Mindset
“The dragon appears in the field. It furthers one to see the great man.”
2. Dragon in the Field — The Abundance Mindset
You launch, and suddenly you’re standing next to other companies with more computing power, more data, and more capital than you’ll ever have. This is where scarcity thinking kills founders, treating AI as a fixed pie that a handful of giants will win.
An abundance mindset realizes that AI is driving the cost of intelligence toward zero, baking an infinitely larger pie. You now have the tools to build things that would have required a much larger engineering team just a few years ago.
3. The Diligent Dragon — The Longevity Mindset
3. The Diligent Dragon — The Longevity Mindset
“All day long the superior man is creatively active. At nightfall his mind is still beset with cares. Danger. No blame.”
This is the grind. You have entered the market and are building furiously, but the psychological and physical pressure is immense. You are active all day, yet anxious at night. To survive this perilous phase of non-stop execution, founders must adopt the Longevity Mindset.
A Yale study led by Professor Becca Levy found that older adults with more positive views of aging lived about 7.5 years longer. For founders, the Longevity Mindset applies this same logic to the body and the organization: you cannot reach the next stage on a burned-out founder or a brittle team. Resilience works as load-bearing infrastructure for the leap itself.
4. Leaping Dragon — The Exponential Mindset
4. Leaping Dragon — The Exponential Mindset
“The dragon leaps over the abyss. No blame.”
This is the scaling phase, the most dangerous part of the journey. To cross the chasm, founders must adopt the Exponential Mindset.
Human brains are wired to think linearly, but AI advances exponentially. The Exponential Mindset means architecting for where the model will be in eighteen months, not where it is on launch day.
Founders who build their product roadmap against today’s capability ceiling are already building a legacy product. You must anticipate the leap, building infrastructure that scales with the compounding intelligence of the models themselves.
5. Flying Dragon — The Moonshot Mindset and Scenario Maturity
5. Flying Dragon — The Moonshot Mindset and Scenario Maturity
“The flying dragon is in the heavens. It furthers one to see the great man.”
The Moonshot Mindset treats “impossible” as an unsolved engineering problem rather than a wall. But a moonshot without a landing site is just a hallucination with better production values. What separates a flying dragon from an expensive fireworks show is Scenario Maturity — a check on whether the specific use case you’ve chosen, not the technology in general, is actually ready to fly.
That means asking harder questions, such as:
Is there a real buyer, with real budget and real urgency, ready to act now rather than someday?
Does the workflow generate a feedback loop that compounds in your favor the longer you run it?
Can today’s models actually do the job reliably at the point of use?
Get that match right, and the moonshot has somewhere to land. Chase ambition alone, and you’ve built a very well-funded crash.
Case in Point: Open Evidence
Open Evidence is an AI-powered medical search engine and clinical decision-support platform that allows verified healthcare professionals to ask complex medical questions and receive rapid answers grounded in peer-reviewed literature. It demonstrates scenario maturity through a precise, high-stakes alignment of buyer, monetization, moat, and capability match:
The Buyer & Monetization: Targeted physicians making time-sensitive decisions at the point of care. Instead of inventing a new budget, it tapped into existing pharmaceutical marketing dollars by keeping the tool free for verified doctors and monetizing via contextually relevant pharma advertising.
The Moat: Built exclusively on peer-reviewed medical journals and direct content partnerships with elite institutions like the American Medical Association and the New England Journal of Medicine. The data asset is compounded by proprietary, verified clinical consultation loops that competitors cannot easily replicate.
The Capability Match: Bounded the problem domain tightly to clinical medicine rather than attempting open-ended consumer chat, allowing current-generation models to maintain exceptional reliability.
That combination, not a superior model, is what turned a niche physician tool into the fastest-scaling case in the sector.
One Line Further: The Arrogant Dragon
One Line Further: The Arrogant Dragon
The Qian hexagram doesn’t stop at the flying dragon. Its sixth and final line describes a dragon that has flown too high — an overreaching dragon with cause for regret. It’s the founder who mistakes access to a powerful model for scenario readiness, and pours capital into the most exciting application instead of the most prepared one.
The lesson isn’t to stop climbing. It’s to keep re-checking, at every altitude, whether the business, the data, and the technology are actually ready for where ambition wants to take you.
The Human Edge: Judgment Over Data
If AI can already process the available information instantly, where does human advantage come from?
Howard Marks, co-founder of Oaktree Capital, drew this line decades before anyone was worried about AI:
first-level thinking stops at the obvious conclusion;
second-level thinking asks what everyone else is missing, and what happens next because of it.
AI has made first-level thinking free — any model can summarize the data, the consensus, the obvious take, instantly. That pushes the entire edge left for founders and investors up to the second level:
Judging the second-order effects of what the data actually implies, not just what it states.
Weighing what can’t be measured — management quality, grit, the structural maturity of a scenario.
Deciding, on conviction, which future is worth building toward before the market has agreed with you.
The Human Edge: Judgment Over Data
AI is an incredibly powerful engine, but it lacks a soul. It lacks intent. Understanding the limitations of AI allows us to shed the victim mindset and reclaim our natural birthright as creators.
No matter how powerful the machine becomes, the human founder still evaluates the scenario and sets the destination – at least for now. We remain in charge of our lives, fully capable of shaping our own destinies.
Do not fear the dragon. Find your scenario, and ride it.
本届 WAIC 最让人惊喜的创业故事，不是大厂的重磅发布，也不是实验室的技术突破，而是一个一人公司（OPC）跑出的项目 ——TideFlow AI 个性化睡眠决策系统。
创始人吴松芸没有医学背景，创业的起点只是自己长期受失眠困扰的真实体验。 她的核心洞察很精准：很多人失眠不是环境不好，而是大脑长期处于高唤醒状态，没法自然从清醒过渡到睡眠。TideFlow 用 AI 实时感知用户状态，动态匹配放松音频、呼吸引导等干预方案，帮大脑自然入睡，区别于市面上千篇一律的白噪音、冥想产品。
Your tokens are cheap. Your model is open-source. So what do you actually own?
That question shaped my review of WAIC 2026, held in Shanghai.
More than 1,100 companies presented over 3,000 exhibits. But the real divide was not between larger and smaller models. It was between technologies that attract attention and those approaching defensible, revenue-generating deployment.
WAIC 2026 Shanghai
Over three days, I examined the most relevant medical AI cases through the Mans International SMAF lens: the Scenario Maturity Assessment Framework, which looks beyond model parameters to assess proprietary data, workflow integration, buyer readiness, trust and commercial scalability.
Three trends stood out and they were not equally mature.
Trend 1: The moat moved from the model to the data
Leading companies are no longer applying general models directly to medical questions; they are building “medically enhanced large models” grounded in exclusive data.
A prime example is Baichuan Intelligence’s “Futang·Baichuan’s pediatric model. It was developed with Beijing Children’s Hospital using the clinical expertise of more than 300 paediatric specialists and decades of high-quality, de-identified medical records.
The results are striking: in a head-to-head against 12 attending and resident physicians on 60 real outpatient cases, it hit 91.7% diagnostic accuracy, nearly 15 points above the human average, with 92% medication-safety compliance. It now lives in daily multidisciplinary clinics and is rolled out to 150+ county hospitals in Hebei.
Trend 1: The moat moved from the model to the data
China also presents a compelling initial scenario. Leading paediatric expertise is concentrated in major hospitals, while primary-care and county-level institutions often lack experienced specialists. AI could help distribute medical expertise more widely, not by replacing doctors, but by allowing expert knowledge to travel across institutions and regions.
SMAF read: A static dataset can eventually be copied. A clinical system that improves through validated feedback from each deployment becomes increasingly trusted and harder to replace.
Trend 2: Embodied AI is dazzling — and still maturity-gated
United Imaging Intelligence’s equipment-data-algorithm stack is a real hardware moat that pure software players can’t easily copy. And the humanoid demos were the crowd favorite: Galaxy General’s “AstraBrain” architecture driving a robot through folding laundry and making breakfast; Fourier Intelligence’s GR-3 Care-bot executing a full intent-to-action loop from a spoken “I’m thirsty”; Optics Valley Dongzhi’s “Photon” robots handling patrol, companionship, and health monitoring in elder-care settings.
Trend 2: Embodied AI is dazzling — and still maturity-gated
Impressive. Not yet mature. Getting a robot from a booth into a home or hospital means clearing three hurdles that don’t show up in a product demo:
Safety — the care recipients are disabled or elderly; failure tolerance is close to zero.
Privacy — continuous in-home data collection needs real consent architecture, not a terms-of-service checkbox.
Humanity — the job is care, not just task completion. A robot that folds shirts perfectly but feels clinical hasn’t solved the actual problem.
SMAF read: high potential, low current maturity. This is the category where the technology outpaces the scenario — worth watching, not yet worth pricing as though it’s solved.
Trend 3: Narrow problem, Real payers — OPC models are proving maturity can be earned fast
The most interesting founder story at WAIC wasn’t a lab spinout. TideFlow AI, an “AI personalized sleep decision system” was built solo by Wu Songyun, no medical background, just her own struggle with insomnia.
Trend 3: Narrow problem, Real payers — OPC models are proving maturity can be earned fast
TideFlow’s core insight is that insomnia often stems not from a poor environment, but from a hyperaroused brain. The system uses AI to perceive the user’s state in real-time, dynamically matching intervention plans to help the brain naturally transition into sleep. After 12 iterations, this highly personalized, lightweight business architecture stepped onto the global stage, acquiring real paying users overseas.
SMAF read: this is what fast-tracked maturity looks like — a narrow, well-defined pain point, a founder close enough to it to iterate quickly, and payers who validate the solution before the funding round does.
The Mans International Takeaway
In this profound transformation, the core of industry competition is undergoing a structural reshaping from “Model IQ” to “Scenario EQ.” This is not short-term technological hype; it is a fundamental shift in the logic of value creation, capture, and defense.
Navigating this structural change requires far more than financial reports and model parameters. It demands a precise grasp of regulatory boundaries and a professional analytical framework capable of systematically assessing scenario maturity and identifying strategic gaps. This is precisely the design intent behind the Mans International SMAF.
Ultimately, every medical AI participant must confront a fundamental question: Is your AI strategy designed to win brief applause at the exhibition booth, or to truly crack the real industry dilemma of waiting three hours to see a doctor for five minutes?
If you’re trying to figure out where a specific medical AI bet actually sits on that maturity curve — or how to position a product for international scaling — that’s the exact gap SMAF was built to close. Happy to compare notes.
Mans International applies the Scenario Maturity Assessment Framework to help technology founders and investors distinguish technical readiness from commercial, workflow and ecosystem readiness—particularly across China and international markets.
The I Ching (Book of Changes) states: “Heaven’s movement is ever vigorous; thus, the noble person constantly strives for self-improvement.” This underlying force of relentless self-renewal, regardless of the circumstances, has found its most extreme validation in the practice of Mr. Cai Lei.
An ALS breakthrough: A master class in Deep-Tech Ecosystem Building, Founder Resilience, and SMAF
In 2019, Mr. Cai Lei, a former vice president of JD.com and one of the pioneers behind China’s electronic invoice system, was diagnosed with amyotrophic lateral sclerosis, or ALS. He was 41. He had just welcomed a new child. His career, family, and life were all at a peak moment.
Then came the diagnosis. ALS is often described as one of the most devastating neurodegenerative diseases. The average survival window after diagnosis is often only a few years.
Seven years later, in 2026, his body function score plummeted from 48 to 4. He is completely paralyzed from the neck down, his vocal cords have severely atrophied, and he relies on a liquid diet and a 24-hour ventilator to survive. Across his entire body, only his eyes remain under his autonomous control.
Cai Lei before and after ALS
Yet, Cai Lei’s story is far more than an inspiring narrative of resilience and empathy. Analyzed through the Scenario Maturity Assessment Framework (SMAF), it stands as a textbook masterclass in deep-tech scenario breakthroughs. It is a blueprint of how to take a globally recognized “unsolvable dead end” and reconstruct it into a high-maturity, self-sustaining ecosystem of research collaboration and commercial translation.
I. Deconstructing the Breakthrough via SMAF: A High-Maturity Super Ecosystem
At Mans International, we utilize the SMAF (Scenario Maturity Assessment Framework) to evaluate the commercial viability and translation potential of deep tech ventures. We have seen too many projects perish in the “slide deck” phase or or “lab-only self-indulgences.”
From a scenario maturity perspective, the true brilliance of Cai Lei’s “ice-breaking” initiative is not simply his unwavering belief, but his methodical execution. He took a highly fragmented, chronically inefficient rare-disease scenario — one lacking adequate resource attention — and orchestrated it into a synchronized system uniting patients, data, research, clinical trials, capital, AI, and public trust.
1. Data and Workflows: From Scattered Patients to R&D Infrastructure
One of the greatest bottlenecks in rare disease R&D is scattered patient populations, scarce biological samples, and a lack of real-world data. Often, research does not lack direction; it lacks a stable, continuous, and actionable data foundation.
The Data Engine: Cai Lei built the “Jianyu Mutual Aid Home,” the world’s largest civilian ALS research database (over 18,000 registered users), housing tens of thousands of structured real-world cases. He also launched an “ALS Research AI Brain,” training 24/7 on over 20 million interdisciplinary papers to automatically filter and evolve targets without burdening researchers.
The Workflow: This 360-degree dynamic vital-sign tracking system compresses notoriously slow clinical recruitment to astonishing speeds — achieving “hour-level” responsiveness (i.e. 700 sign-ups in 2 hours; launching clinical trials within 3 months).
Data and Workflows: From Scattered Patients to R&D Infrastructure
2. The Business Closed Loop: A Mechanism for Long-Term Sustenance
Rare disease research cannot survive solely on short-term donations or one-off grants. Drug discovery features long cycles, high failure rates, and relentless capital demands, while external funding environments and public attention fluctuate. Without a stable financial engine, even the grandest mission will bleed out mid-way.
The partnership forged between Cai Lei and his wife, Duan Rui, perfectly demonstrates the synergy of vision and operations. Many view Duan Rui’s live-streaming efforts purely as a “wife’s sacrifice.” While deeply moving and true, from a strategic perspective, it is a brilliantly designed commercial closed loop.
Cai Lei continually raises the ceiling of their mission — connecting patients, scientists, pharma, and society. Meanwhile, Duan Rui absorbs the immense operational realities: live-streaming revenue, team management, cash flow, cost control, and risk mitigation. This closed-loop of “front-end commercial revenue funding back-end R&D burn” provides a continuous lifeline for a highly uncertain, long-cycle scientific endeavour.
The Business Closed Loop: A Mechanism for Long-Term Sustenance
3. Narrative & Ecosystem: Evolving from Empathy to Industry Consensus
Before Cai Lei, ALS was trapped in a weak narrative within public and industry discourse — viewed merely as an “incurable and unprofitable” tragedy. It garnered generalized sympathy but lacked actionable pathways.
Cai Lei elevated this narrative fundamentally. He did not stop at emotional appeals for awareness; he broke down rare-disease R&D into actionable industry propositions. He allowed the scientific community, the biotech industry, and the public to clearly see their specific roles and value.
This mature narrative has penetrated industry silos, uniting over 60 global research teams and 50+ biotech companies, transforming an untouched “cold sector” into a highly coordinated battlefield with shared consensus, pooled resources, and a synchronized tempo.
Narrative & Ecosystem: Evolving from Empathy to Industry Consensus
II. The Founder’s Mirror: Resilience for Global Founders
In his recent “Countdown” speech on Global ALS Day, June 21, 2026, Cai Lei said he had already defeated an enemy more terrifying than ALS: despair.
For founders today — navigating agonizing market cycles and high-stakes survival tests — Cai Lei’s mental fortitude serves as a profound mirror:
Reject the Victim Mentality. Complaining about the macro environment or the “capital winter” yields zero value. Completely paralyzed and unable to speak, Cai Lei never wallowed in the unfairness of fate. He immediately pivoted his strategy, utilizing an eye-tracking device to launch a race against time. Radical acceptance and execution to the absolute limit are the foundational ethics of a founder.
Pry Open Incremental Gaps in Dead Ends. Cai Lei noted: “You might think there is only a solid wall in front of you. But look down, there might be a path; turn sideways, there is a gap. You can even choose to climb over or dig through.” When traditional funding tightens and cross-border barriers rise, a founder’s core competency is leveraging tools — like AI and cross-disciplinary ecosystems — to pry open growth spaces ignored by the mainstream.
Anchor Your Venture in a Grand Proposition.“The best way to overcome fear is to place yourself within a much greater cause.” When your corporate vision is tied to core societal challenges — hard tech breakthroughs, life sciences, energy transitions — the resilience you unlock will far surpass what secular fame or profit can sustain.
Pry Open Incremental Gaps in Dead Ends
III. Conclusion: The Countdown is a Prelude to Victory
In Cai Lei’s room, four clocks sit ticking. The media calls it the countdown of his life. He corrects them: “This is my countdown to ALS.”
“If my eyes fail, I will connect to a Brain-Computer Interface. If my brain stops turning, I will upload my consciousness to an embodied robot. I have marched all the way to the face of this terminal illness, and I am not here to surrender.”
As heaven’s movement is ever vigorous, so must a leader ceaselessly strive along.
The Countdown is a Prelude to Victory
Here is to all the founders who keep walking through the valleys of economic cycles. Here is to the researchers grinding relentlessly in their labs. Here is to all those who refuse to bow to fate.
Do not ask where the hope lies. Keep moving forward, and hope will reveal itself. As long as you do not retreat, every direction is the way forward.
Global Strategic Partnership
Leading global research institutions, multinational pharmaceutical companies, biotech innovators, and international funds are invited to partner with Mans International to access and navigate high-maturity life science and deep-tech ecosystems.
Through our SMAF — Scenario Maturity Assessment Framework — we help identify where technology, capital, clinical resources, market readiness, and ecosystem trust can be precisely aligned.
Our goal is to reduce cross-border and cross-sector friction, accelerate clinical and commercial translation, and support breakthrough technologies and strategic capital in moving from promise to real-world impact.
Last week, I sat down with several health tech founders to stress-test their business models. The conversation kept circling back to a hard truth: in health tech, brilliant technology doesn’t guarantee survival.
In February 2026, Kintsugi — a pioneer in AI-powered voice biomarkers for depression detection — announced it was winding down commercial operations. This was not a failure of science. The company had developed models trained on tens of thousands of voice samples, demonstrated genuine clinical promise, and generated real enterprise interest. So what went wrong?
1. The “New Category” Trap
Kintsugi was selling into a nascent market: AI-based mental health diagnostics. That immediately triggers three enterprise questions that are genuinely hard to answer quickly:
Is it clinically accurate?
Is it biased across accents, languages, or demographics?
Who bears liability when it misses or misclassifies?
Answering these requires years of market education. Education is time-consuming, capital-intensive, and rarely aligns with venture pacing. Clinically, early depression detection matters. Commercially, it rarely triggers a fast procurement cycle.
2. Correlation ≠ Causation
I emphasize this to founders constantly: buyers don’t pay for correlation. They pay for causation.
Even if your model detects depression with high sensitivity, a health system will ask a precise follow-up: “How does this move our specific metrics?” Early detection benefits patients, but you must prove it lowers acute care spend or improves value-based reimbursement performance. Mental health tools often create profound long-term clinical value. Enterprise buyers, however, operate on short-term budget logic. That gap is the seller’s problem to close, not the buyer’s problem to overlook.
3. Buyer Ambiguity Kills Momentum
This is where I apply the Scenario Maturity Assessment Framework (SMAF) — a diagnostic I used to help founders identify exactly where they are in the buyer-readiness lifecycle before committing capital to a sales motion.
The Scenario Maturity Assessment Framework asks a foundational question most founders skip: not “who could benefit from this?” but “which buyer, in which scenario, is mature enough to act right now?” Maturity here means they have the budget authority, the internal problem recognition, and the procurement trigger already in motion.
Kintsugi’s addressable market included hospitals, telehealth platforms, clinics, and employers. On an SMAF assessment, this maps to a fragmented scenario landscape. When you’re navigating multiple buyers with divergent incentives, compliance requirements, and approval timelines, the result is predictable: no one buys quickly.
The discipline SMAF enforces is uncomfortable but non-negotiable: identify the one buyer scenario where maturity is highest, build your entire first commercial motion around that wedge, and treat every other segment as a future phase — not a current pipeline.
The Runway vs. Regulatory Mismatch
Then came the structural wall. Kintsugi pursued FDA De Novo clearance for a novel AI diagnostic category. That pathway demands years of evidence generation, expensive consultants, iterative submissions, and regulatory uncertainty. The company reportedly exhausted its runway waiting for final clearance.
Venture timelines expect product-market fit in 18 to 24 months; healthcare regulatory pathways operate on a 5- to 7-year horizon. That gap demands you design your funding strategy, commercial roadmap, and regulatory sequence as a single, integrated plan from day one.
What Founders Should Take From This
Kintsugi’s shutdown is not a repudiation of voice biomarker science. The underlying research remains valid. This is a structural lesson about what it takes to survive long enough to commercialize a genuinely novel clinical technology in a regulated environment.
Before your next raise, pressure-test these three questions and be honest about the answers:
Who exactly will sign the PO? (Not who could benefit, but who holds the budget, authority, and incentive to buy now?)
What causation outcome triggers the purchase? (Cost avoidance? Risk mitigation? Reimbursement lift?)
Does your runway cover the full clearance-to-commercialization timeline? (If not, what non-clinical or bridge revenue extends it?)
AI Hallucination Survival Guide: Case Studies, Causes, and Prevention Strategies
Have You Ever Been “Fooled” by AI? — The $5,000 Lesson from a Lawyer
Let’s start with a real case: Steven A. Schwartz, a veteran lawyer with over 30 years of experience, was fined $5,000 for submitting AI-generated false information in court.
In 2023, Schwartz represented Roberto Mata in a lawsuit against Avianca Airlines. Mata claimed he injured his knee after being struck by a metal food cart during a flight. Schwartz used ChatGPT for legal research to support his case and cited multiple “court cases” in his legal brief. However, the judge soon discovered that these cases didn’t exist in any legal database.
Schwartz later recalled that he specifically asked ChatGPT whether the cases were real, and the AI confidently assured him they were.
Unfortunately, he was misled by AI hallucinations.
Today, let’s talk about AI hallucinations — why AI sometimes makes things up and how to avoid being misled by it.
What Is AI Hallucination?
AI Hallucination is when the content generated by a large language model like ChatGPT looks reasonable but is completely fictitious, inaccurate, or even misleading.
For example:
You ask AI: “Who invented time travel?”
AI responds: “Dr. John Spacetime invented time travel in 1892 and was awarded the Nobel Prize in Physics for his discovery.”
Sounds fascinating, right? But there’s a problem — it’s completely false! Dr. John Spacetime doesn’t exist, time travel hasn’t been invented, and the Nobel Prize wasn’t even established until 1901.
How Does AI Hallucination Happen?
According to a research team led by Professor Shen Yang at Tsinghua University, AI hallucinations mainly stem from five key issues:
1. Data Availability Issues — AI relies on training data that may be incomplete, outdated, or biased.
2. Limited Depth of Understanding — AI struggles with complex questions and often makes assumptions.
3. Inaccurate Context Interpretation — AI may misinterpret the context of a query, leading to misleading responses.
4. Weak External Information Integration — AI cannot access or verify real-time external information and depends solely on existing data.
5. Limited Logical Reasoning & Abstraction — AI often makes logical reasoning and abstract thinking errors, especially for complex tasks.
Image source: Types of AI hallucinations summarized by Professor Shen Yang’s team.
Types of AI Hallucinations
Based on these factors, AI hallucinations can be categorized into five main types:
1. Data Misuse — AI misinterprets or incorrectly applies data, resulting in inaccurate outputs.
2. Context Misunderstanding — AI fails to grasp the background or context of a query, leading to irrelevant or misleading answers.
3. Information Fabrication — AI fills gaps with made-up content when lacking necessary data.
4. Reasoning Errors — AI makes logical mistakes, leading to incorrect conclusions.
5. Pure Fabrication — AI generates entirely fictional information that sounds plausible but has no basis in reality.
Tips to Protect Yourself from AI Hallucinations
AI hallucinations are inevitable, but you can reduce the risk of being misled by improving how you interact with AI. Here are two simple yet effective strategies:
1. Give Clear Instructions — Don’t Make AI “Guess”
— Be specific: Vague prompts can cause AI to “fill in the blanks” with incorrect information. Instead of asking, “Tell me some legal cases,” ask, “List U.S. federal court cases related to aviation accidents from 2020.”
— Set boundaries: Define limits for AI responses, such as “Use Xiaomi’s 2024 Financial Statement.”
— Request sources: Ask AI to provide citations or references so you can verify the information.
2. Verify AI’s Output — Don’t Trust It Blindly
— Check sources: If AI provides references, make sure they exist and are credible. Verify citations from websites or academic papers.
— Stay skeptical: Treat AI-generated content as a reference, not absolute truth. Use your own expertise and common sense to assess accuracy.
— Cross-check with other tools: Use multiple AI platforms to answer the same question and compare the results.
Remember, no matter how smart AI seems, it’s just a tool — the real judgment lies with you. Instead of getting tricked by AI, learn how to outsmart it!
Key Considerations for Choosing an AI Hallucination Detection Tool
With the rise of AI-generated content, many companies now offer solutions to help businesses detect and mitigate AI hallucinations. While I do not endorse specific providers, here are some key factors to consider when making a selection.
1. Core Evaluation Criteria
The most important aspect is assessing how the tool conducts fact-checking. Look for:
— The evaluation metrics it uses to measure AI accuracy.
— Whether it provides detailed explanation reports that clearly identify hallucinations, explain their causes, and cite reliable sources.
2. Advanced Features to Match Your Needs
Depending on your company’s specific use case, consider whether the tool offers:
— Real-Time Verification Pipelines — Detects and corrects hallucinations as AI generates content.
— Multimodal Fact-Checking — Simultaneously verifies text, images, and audio for accuracy.
— Self-Healing AI Models — Automatically corrects inaccurate outputs without human intervention.
— Enterprise-Specific Knowledge Integration — Custom AI fact-checking models tailored to private datasets.
3. Unique Differentiators
Some providers offer specialized features that may align with your company’s budget and requirements, such as:
— Synthetic Data Generation for Hallucination Training — Creates controlled datasets to enhance AI verification models.
— Crowdsourced Human Review — Combines AI detection with expert reviewers for hybrid verification.
— Legal & Compliance Fact-Checking — Monitors AI-generated content for regulatory and contractual compliance.
— Proprietary Transformer-Based Verification — Uses a unique AI architecture optimized for detecting hallucinations.
Choosing an AI hallucination detection tool is fundamentally about balancing the Accuracy–Cost–Scalability triangle. It’s essential to address current business pain points, pinpoint the affected processes, weigh costs against benefits, and ensure flexibility for future tech upgrades and expansion.
